PITPNA and prostate carcinoma: Through sequence alignment analysis, it was found that the PITPNA-AS1 sequence had binding sites with miR-129-5p, as shown in Fig. 3A. RIP assay were conducted in prostate cancer cells, and the results showed that Ago2 antibody could significantly enrich PITPNA-AS1, suggesting that PITPNA-AS1 could interact with Ago2 (Fig. 3B), which indirectly proved that PITPNA-AS1 had the ability to bind miR-129-5p.